PTGX Key Statistics, Chart & Performance
The current stock price of PTGX is 90 USD. In the past month the price increased by 15.61%. In the past year, price increased by 105.48%.
PTGX Latest News, Press Relases and Analysis
PTGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About PTGX
Company Profile
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 130 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Company Info
PROTAGONIST THERAPEUTICS INC
7707 Gateway Blvd Ste 140
Newark California CALIFORNIA 94560 US
CEO: Dinesh V. Patel
Employees: 126
Phone: 15104740170
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you describe the business of PROTAGONIST THERAPEUTICS INC?
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 130 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Can you provide the latest stock price for PROTAGONIST THERAPEUTICS INC?
The current stock price of PTGX is 90 USD. The price decreased by -0.08% in the last trading session.
Does PROTAGONIST THERAPEUTICS INC pay dividends?
PTGX does not pay a dividend.
How is the ChartMill rating for PROTAGONIST THERAPEUTICS INC?
PTGX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the expected growth for PTGX stock?
The Revenue of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -80.16% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for PTGX stock?
PROTAGONIST THERAPEUTICS INC (PTGX) currently has 126 employees.
PTGX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PTGX. When comparing the yearly performance of all stocks, PTGX is one of the better performing stocks in the market, outperforming 95.89% of all stocks.
PTGX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PTGX. PTGX has an excellent financial health rating, but there are some minor concerns on its profitability.
PTGX Financial Highlights
Over the last trailing twelve months PTGX reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS decreased by -76.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 21.94% | ||
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| Debt/Equity | 0 |
PTGX Forecast & Estimates
20 analysts have analysed PTGX and the average price target is 91.65 USD. This implies a price increase of 1.84% is expected in the next year compared to the current price of 90.
For the next year, analysts expect an EPS growth of -148.12% and a revenue growth -80.16% for PTGX